secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001628280-23-027767
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q2 product rev $68.9M (+45% YoY); VYVGART approved in China; net loss $120.9M
--------------------------------------------------------------------------------

- Product revenue $68.9M, up 45% YoY (53% constant currency); driven by ZEJULA $43.0M, Optune $13.7M.
- Net loss $120.9M ($0.13 loss per ADS) vs $137.9M loss a year ago; R&D spend $76.7M, SG&A $67.9M.
- Cash $876.4M as of June 30, 2023; down from $931.4M at March 31, 2023.
- NMPA approved VYVGART (efgartigimod) for gMG; launch preparation underway; NRDL listing eligible for 2024.
- Promoted Yajing Chen to CFO effective July 7, 2023; targeting corporate profitability by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023027767/0001628280-23-027767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023027767/zlab-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer